Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematological malignancies.

  • 1 views
  • 14 May, 2022
  • 17 locations
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

-cancer agents in participants with advanced malignancies.

antineoplastic
oophorectomy
  • 28 views
  • 25 Mar, 2022
  • 5 locations
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (ENCORE)

This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration

  • 0 views
  • 17 Mar, 2022
  • 1 location
Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer (CEDAR)

. More advanced radiotherapy techniques, that result in fewer toxicities, means that we are now able to combine new anti-cancer agents into standard treatment. Targeting the tumour early in this

  • 5 views
  • 12 Feb, 2022
  • 1 location
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to

  • 68 views
  • 17 May, 2022
  • 17 locations
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

triple negative breast cancer
paclitaxel
breast cancer
trastuzumab
HER2
  • 445 views
  • 23 May, 2022
  • 32 locations
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Treatment with polysorbate 80-solved Docetaxel (Taxotere®) is hampered by the requirement to co-administer steroids. Chronic (intermittent) steroids are negatively impacting bone health and have well known immunosuppressive effects. Despite steroid premedication, polysorbate 80-solved Docetaxel (Taxotere®) results in occasional infusion reactions due to the solvent polysorbate 80. Docetaxel micellar is a …

  • 0 views
  • 07 Jan, 2022
  • 3 locations
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity

chemotherapeutic agent
paclitaxel
parp inhibitor
antineoplastic
carboplatin
  • 17 views
  • 16 May, 2022
  • 23 locations
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

stage iv non-small cell lung cancer
durvalumab
recurrent non-small cell lung cancer
  • 132 views
  • 21 Apr, 2022
  • 32 locations
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07)

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive

  • 0 views
  • 25 May, 2022
  • 55 locations